Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,318 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07123415RecruitingPhase 1
Study of APX-343A alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called APX-343A, either by itself or in combination with the immunotherapy pembrolizumab, for people with advanced solid tumors that have not responded to prior treatments.
SeongnamAges 19 years+ - NCT07512583RecruitingPhase 1/Phase 2
TQB2930 injection for advanced solid tumors with HER2 expression
This study tests a new injection called TQB2930 designed to treat advanced solid cancers (cancers that have spread) that have HER2 protein on their surface. The goal is to see if this treatment can shrink these tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07004647Recruiting
MT027 cell injection for advanced peritoneal tumors
This trial tests an experimental cell therapy, MT027, for people with advanced peritoneal tumors that have stopped responding to standard treatments. The goal is to see if MT027 can shrink tumors when injected directly into the abdomen.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05785754RecruitingPhase 1
Early drug study for advanced solid tumors
This Phase 1 study tests DCSZ11 in people with advanced or metastatic solid tumors (cancers that can’t be removed or have spread) given alone or with other treatments. It’s designed to find a safe dose and to see whether the treatment shows signs of shrinking cancer.
Birmingham, AlabamaAges 18 years+ - NCT06041503RecruitingPhase 2
Treating rare bladder and testicular cancers with targeted therapy
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) for people with certain rare cancers of the urinary tract or testicles. The goal is to see if these treatments can shrink tumors or stop them from growing.
Bethesda, MarylandAges 18–120 - NCT06241898RecruitingPhase 1
First study of a new drug for advanced solid tumors
This study tests a new drug (BB-1709) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it's safe and how well it works.
Beijing, Beijing MunicipalityAges 18–78 - NCT06958679RecruitingPhase 1
Study of SYS6005 for advanced solid tumors and lymphomas
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
TianjinAges 18 years+ - NCT07071090RecruitingPhase 1
Study of DC50292A for advanced solid tumors with MTAP deletion
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
Fuzhou, FujianAges 18 years+ - NCT07407504RecruitingPhase 1
GenSci145 for advanced solid tumors with PIK3CA mutation
This trial tests a new oral drug, GenSci145, alone or with other drugs, for people whose advanced cancer has a PIK3CA gene change and has grown after standard treatments. It aims to see if this drug can help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07404202Recruiting
HER2 testing study for several cancer types
This study looks at a test called HER2 IHC (a way to check for a protein called HER2 on tumor cells) in people with certain cancers: non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), gynecological cancers (cervical, endometrial, ovarian), and urothelial cancer (UC). It aims to see how well the test works in different patients. You may join if you have enough stored tumor tissue from a biopsy or surgery done within the past 5 years.
BeijingAges Any age - NCT07401316Recruiting
Tracking germ cell tumors with a blood test for cancer DNA
This trial looks for signs of cancer DNA in your blood (circulating tumor DNA) to see if it can help track germ cell tumors. It may help doctors find out if your cancer is coming back earlier.
Indianapolis, IndianaAges 18 years+ - NCT07606612RecruitingPhase 1
Testing SI-B036 in Advanced Solid Tumors
This early-stage trial tests a new drug called SI-B036 in patients with advanced cancers that have spread or cannot be completely removed by surgery. The goal is to understand how safe the drug is and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07417072Recruiting
Brain tumor drug testing using 3D models in children
This study creates 3D models from brain tumor tissue of children aged 3-18 to test how different drugs might work against their specific tumor. The goal is to find more personalized treatments.
Florence, FirenzeAges 3–18 - NCT07372625RecruitingPhase 1
How rezatapopt affects common drugs in advanced solid tumors with TP53 Y220C mutation
This trial tests how rezatapopt changes the way your body processes four common medicines (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific TP53 Y220C gene change. It helps doctors understand the right dose for future patients.
Denver, ColoradoAges 18 years+ - NCT07441460RecruitingPhase 3
KN026 plus HB1801 after surgery for HER2-positive breast cancer
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07436728RecruitingPhase 1/Phase 2
Study of TAK-505 for adults with solid tumors
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
Orange, CaliforniaAges 18 years+ - NCT07359066RecruitingPhase 1/Phase 2
SPR1020 for advanced solid tumors with DNA repair defects
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06233942RecruitingPhase 1
Testing a new drug for advanced solid tumors
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07356453RecruitingPhase 1
Study of PARG inhibitor FORX-428 for advanced solid tumors
This trial tests a new drug called FORX-428, which targets a protein called PARG, in people with advanced solid tumors. It is for patients whose cancer has not responded to prior treatments and who have specific genetic changes, such as BRCA mutations.
Palo Alto, CaliforniaAges 18 years+ - NCT06352359RecruitingPhase 1
Study of ONC 841 for advanced solid tumors
This phase 1 study tests an experimental drug called ONC 841 for people with advanced solid tumors that have not responded to other treatments. The trial aims to find a safe dose and see if the drug can shrink tumors.
Sacramento, CaliforniaAges 18 years+ - NCT06365840RecruitingPhase 2
Study of IMC-001 for advanced tumors with high mutations
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
GoyangAges 19 years+ - NCT04855656RecruitingPhase 1
Lunresertib for advanced solid tumors with specific gene changes
This early-phase trial tests lunresertib alone or with other study drugs in people with advanced solid tumors that have certain tumor gene changes. It aims to see whether the treatment is safe and whether it can help shrink or control cancer.
Los Angeles, CaliforniaAges 12 years+ - NCT06927297RecruitingPhase 1
Safety study of a mitochondrial vaccine for advanced solid tumors
This early-phase trial tests a new type of cancer vaccine designed to help your immune system attack tumors. It is for people with advanced solid tumors who have run out of standard options.
Chengdu, SichuanAges 18–75 - NCT05687682RecruitingPhase 1
AM-928 infusion safety study for advanced solid tumors
This Phase 1 trial tests how safe AM-928 is when given through an IV infusion to people with advanced solid cancers that can’t be removed by surgery and have stopped responding to standard treatments. It may help doctors learn the safest dose and whether the drug causes side effects worth watching.
TaipeiAges 18 years+
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,318 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.